1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Leber Congenital Amaurosis (LCA) - Drugs In Development, 2022, provides an overview of the Leber Congenital Amaurosis (LCA) (Genetic Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Leber congenital amaurosis is an eye disorder that primarily affects the retina, which is the specialized tissue at the back of the eye that detects light and color. This condition is the most common cause of inherited blindness in childhood. Symptoms include vision loss, roving eye movements, deep-set eyes, developmental delay, epilepsy, and motor skill impairment.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Leber Congenital Amaurosis (LCA) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Leber Congenital Amaurosis (LCA) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Leber Congenital Amaurosis (LCA) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Leber Congenital Amaurosis (LCA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 12 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.
Leber Congenital Amaurosis (LCA) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Leber Congenital Amaurosis (LCA) (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Leber Congenital Amaurosis (LCA) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Leber Congenital Amaurosis (LCA) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Leber Congenital Amaurosis (LCA) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Leber Congenital Amaurosis (LCA) (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Leber Congenital Amaurosis (LCA) (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Leber Congenital Amaurosis (LCA) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Leber Congenital Amaurosis (LCA) - Overview
- Leber Congenital Amaurosis (LCA) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Leber Congenital Amaurosis (LCA) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Leber Congenital Amaurosis (LCA) - Companies Involved in Therapeutics Development
- Leber Congenital Amaurosis (LCA) - Drug Profiles
- Leber Congenital Amaurosis (LCA) - Dormant Projects
- Leber Congenital Amaurosis (LCA) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Leber Congenital Amaurosis (LCA), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Leber Congenital Amaurosis (LCA) - Pipeline by Atsena Therapeutics Inc, 2022
- Leber Congenital Amaurosis (LCA) - Pipeline by Editas Medicine Inc, 2022
- Leber Congenital Amaurosis (LCA) - Pipeline by Generation Bio Co, 2022
- Leber Congenital Amaurosis (LCA) - Pipeline by Hubble Therapeutics Inc, 2022
- Leber Congenital Amaurosis (LCA) - Pipeline by Huida (Shanghai) Biotechnology Co Ltd, 2022
- Leber Congenital Amaurosis (LCA) - Pipeline by IVERIC bio Inc, 2022
- Leber Congenital Amaurosis (LCA) - Pipeline by LuxFiat Therapeutics LLC, 2022
- Leber Congenital Amaurosis (LCA) - Pipeline by MeiraGTx Holdings Plc, 2022
- Leber Congenital Amaurosis (LCA) - Pipeline by Ocugen Inc, 2022
- Leber Congenital Amaurosis (LCA) - Pipeline by Odylia Therapeutics Inc, 2022
- Leber Congenital Amaurosis (LCA) - Pipeline by Opus Genetics Inc, 2022
- Leber Congenital Amaurosis (LCA) - Pipeline by ProQR Therapeutics NV, 2022
- Leber Congenital Amaurosis (LCA) - Pipeline by Variant, 2022
- Leber Congenital Amaurosis (LCA) - Dormant Projects, 2022
List of Figures
- Number of Products under Development for Leber Congenital Amaurosis (LCA), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Atsena Therapeutics Inc
- Editas Medicine Inc
- Generation Bio Co
- Hubble Therapeutics Inc
- Huida (Shanghai) Biotechnology Co Ltd
- IVERIC bio Inc
- LuxFiat Therapeutics LLC
- MeiraGTx Holdings Plc
- Ocugen Inc
- Odylia Therapeutics Inc
- Opus Genetics Inc
- ProQR Therapeutics NV
- Variant
